EMEA-000060-PIP05-14-M01

Key facts

Invented name
Ilaris
Active substance
Canakinumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0239/2015
PIP number
EMEA-000060-PIP05-14-M01
Pharmaceutical form(s)
  • Solution for injection
  • Powder for solution for injection
  • Powder and solvent for solution for injection
Condition(s) / indication(s)
Treatment of tumour necrosis factor receptor associated periodic syndrome
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novartis Europharm Ltd
Switzerland
Tel. +41 613241111
E-mail: paediatric.enquiries@novartis.com
 
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000060-PIP05-14-M01
Compliance opinion date
26/02/2016
Compliance outcome
positive

Decision

How useful was this page?

Add your rating